← All Sponsors
SPONSOR

Fusion Pharmaceuticals Inc.

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Metastatic Castration-resistant Prostate Cancer
NCT06402331 Phase 2
Recruiting

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
United States View Trial →